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Abstract
Disease recurrence (locoregional, distant) exerts a significant clinical impact on the survival of estrogen receptor–positive
breast cancer patients. Many of these recurrences occur late, more than 5 years after original diagnosis, and represent a major
obstacle to the effective treatment of this disease. Indeed, methods to identify patients at risk of late recurrence and thera-
peutic strategies designed to avert or treat these recurrences are lacking. Therefore, an international workshop was convened
in Toronto, Canada, in February 2018 to review the current understanding of late recurrence and to identify critical issues
that require future study. In this article, the major issues surrounding late recurrence are defined and current approaches
that may be applicable to this challenge are discussed. Specifically, diagnostic tests with potential utility in late-recurrence
prediction are described as well as a variety of patient-related factors that may influence recurrence risk. Clinical and thera-
peutic approaches are also reviewed, with a focus on patient surveillance and the implementation of extended endocrine
therapy in the context of late-recurrence prevention. Understanding and treating late recurrence in estrogen receptor–
positive breast cancer is a major unmet clinical need. A concerted effort of basic and clinical research is required to confront
late recurrence and improve disease management and patient survival.
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Recurrence 5 years or more after a diagnosis is commonly re-
ferred to as “late recurrence” and accounts for about one-half of
all recurrences of estrogen receptor–positive (ERþ) breast cancer
(BC), whereas it is considerably less common in receptor-
negative disease. Identifying who is at greatest risk for late re-
currence and developing strategies to prevent it has emerged as
a major unmet need (Figure 1 in Pan et al.) (1). To address this is-
sue, an international workshop was convened in Toronto,
Canada, in February 2018 that involved clinicians, trialists, sci-
entists, and funders with expertise and/or interest in late recur-
rence (a list of participants is included as an Supplementary
Appendix, available online). The goal of this workshop was to
review current knowledge about the issue of late recurrence in
this patient population and to make recommendations for fu-
ture research strategies. This article summarizes the workshop
discussions regarding our current understanding of the risk of
late recurrence and related clinical issues. A companion article
(2) discusses potential biomarkers of late recurrence and details
research recommendations. Here, we begin by providing a
working definition of late recurrence and by reviewing our cur-
rent understanding of the biological factors contributing to late
recurrence, the clinicopathologic features associated with late
recurrence, and current therapeutic interventions to potentially
prevent it.
Current Understanding of the Problem of Late
Recurrence
Earlier diagnosis of BC as a result of screening, coupled with the
use of more effective systemic adjuvant therapy to prevent
recurrences, has significantly improved clinical BC outcomes,
particularly during the first 5 to 10 years after diagnosis.
Adjuvant chemotherapy and anti-HER2–directed therapy sub-
stantially reduce the risk of recurrence, with the greatest risk re-
duction noted within the first 5 years. Adjuvant endocrine
treatment (ET) also reduces recurrence risk in patients with ERþ
BC, with benefits observed within the first 5 years and also after
completing a 5-year course due to “carryover effect” associated
with tamoxifen in particular.
In the workshop, we defined late recurrence as that occur-
ring more than 5 years after diagnosis and focused our delib-
erations on distant (metastatic) recurrence as opposed to
local-regional recurrence or new ipsilateral or contralateral
primary occurrences. Although the annual risk of distant re-
currence is higher in the first 5 years of follow-up and is de-
creased by adjuvant chemotherapy and ET, as many as one-
half of the life-threatening BC recurrences and deaths in
patients with ERþ HER2 BC take place in the succeeding
15 or more years, often after completion of adjuvant hor-
monal therapy (1). There is an urgent, unmet need to identify
factors beyond standard clinical and pathologic features that
affect the risk of recurrence and inform treatment decisions
in individual patients.
The risk of late recurrence raises the need for more aggres-
sive or novel therapeutic approaches. However, these therapies
are not without side effects, including potentially rare but life-
threatening toxicities, and with important financial costs. Thus,
as with all therapies, the goal is for clinicians to identify the ma-
jority of patients who will never recur and do not need addi-
tional therapy vs those who are at risk. This discrimination
would be facilitated by enhanced understanding of why late
recurrences occur and by the development of methods to
identify individual patients who are at risk of late recurrence,
with a focus on those at imminent risk (ie, within the next
1–2 years) for whom intervention may be effective in pre-
venting recurrence.
Figure 1. Association between pathological nodal status and the risk of distant
recurrence or death from breast cancer (BC) during the 20-year study period.
Shown are data regarding the risk of distant recurrence (A) and death from BC
(B) among 74 194 women with estrogen receptor–positive T1 or T2 disease who
were enrolled in 78 trials at year 0 and were scheduled to receive 5 years of en-
docrine therapy. (Data for another 10 200 women who enrolled in 10 trials after
year 0 are not shown here.) The risk was calculated according to the patients’
pathological nodal status at the time of diagnosis: N0, N1–3, or N4–9. The num-
ber of events and annual rate are shown for the preceding period (eg, data for
years 0–4 are shown at 5 years). The I bars indicate 95% confidence intervals.
The dashed lines indicate that the event rate is for the whole 5-year period
rather than for individual years, as is otherwise shown. The annual rate of death
from BC was estimated by subtracting the death rate in women without recur-
rence from the rate in all women. From (1). Copyright © (2017) Massachusetts
Medical Society. Reprinted with permission from the Massachusetts Medical
Society and the Early Breast Cancer Trialists’ Collaborative Group.
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Estimating Risk of Late Recurrence in Patients
with ER1 Early-Stage BC
Traditional tumor-specific characteristics in patients with ERþ
BC are significantly associated with clinical risk of recurrence
out to at least 20 years postdiagnosis. In a patient-level meta-
analysis, patients within each tumor diameter and nodal status
(TN) category exhibited an appreciable risk of recurrence, with
risk increasing with larger tumor size and nodal status (Table 1
[1]). For example, patients with T1N0 disease exhibited a 13%
risk of distant recurrence from 5 to 20 years post diagnosis. This
distant recurrence rate is in comparison with those patients
with T1N1 and T2N1 cancers who had a risk of 20% and 26% be-
tween 5 and 20 years postdiagnosis and those with T1N2 and
T2N2 cancers with a 34% and 41% risk, respectively. Among
patients with T1N0 BCs, risk was higher with increasing
tumor grade; risk of distant recurrence between 5 and 20 years
postdiagnosis was 10% in those with low-grade tumors com-
pared with 17% in those with high-grade tumors (1). It is possi-
ble that these data overestimate contemporary rates of late
recurrence because of recent improvements in the treatment of
ERþ BC, the implementation of more accurate tumor staging,
and the possibility of suboptimal treatment adherence in earlier
patient cohorts. However, they highlight the importance of
characterizing the underlying mechanisms of late recurrence
and the development of monitoring and treatment strategies
for BC patients beyond 5 years postdiagnosis. Indeed, the clini-
cal treatment score after 5 years (https://www.cts5-calculator.
com/) is a clinically validated algorithm that integrates tumor
characteristics, including size, grade, number of positive axillary
lymph nodes, and age (at diagnosis), to provide an estimate of
the risk of recurrence over the ensuing 5 years, which may facil-
itate providing an accurate estimate of late recurrence risk at
10 years for patients who are cancer free at 5 years (3,4).
However, these standard clinicopathologic features, although
prognostic, are far from ideal predictors of who is at risk of late
recurrence and do not provide sufficient guidance to make treat-
ment decisions at the individual level because a substantial num-
ber of patients in each risk group will not experience a relapse
within the 20-year follow-up period. In this regard, several diag-
nostic tests and scores derived from analyses of the primary tu-
mor have been developed to identify patients at risk of early or
late recurrence vs patients for whom deescalation of treatment is
appropriate (4). These tests include the immunohistochemical 4
(IHC4) protein test, 21-gene Recurrence Score (OncotypeDx),
PAM50 intrinsic subtype (ProSigna), 12-gene Recurrence Score
(EndoPredict), 2-component Breast Cancer Index (based on the
molecular grade index and HOXB13: IL17BR), and 70-gene signa-
ture (Mammaprint) (5–17) (Table 2).
Each of the six assays has been evaluated in at least one
dataset and reported to have prognostic utility beyond the first
5 years for patients who have achieved that milestone on adju-
vant ET without a recurrence (4,18,19). However, each of these
studies has been a “prospective retrospective” study, applying
the assay to archived tissue specimens collected previously
from patients who participated in prospective trials. Of these
assays, only the 2-component Breast Cancer Index was shown
to be predictive of benefit from letrozole after a prior 5-year
course of tamoxifen (19). Although the use of prospective-
retrospective studies is an acceptable strategy to determine
clinical utility, it has been suggested that at least 2 or more
studies derived from different datasets showing similar, if not
identical, results are required before the assay could be consid-
ered to achieve clinical utility (20). For some of the assays,
efforts to validate the late prognostic effect have resulted in
mixed results, and for others no validation studies have been
reported. Thus, neither the American Society of Clinical
Oncology nor the National Cancer Center Network suggests us-
ing the results of these assays in the primary tumor to guide
decisions for patients who have reached 5 years without a
recurrence.
Surveillance Imaging and Serologic Tests for
Identification of Asymptomatic Late
Recurrences
One potential approach to identifying patients at risk of late re-
currence is to perform routine surveillance (radiographic or
scintigraphic imaging and/or circulating liver- and bone-related
enzymes or tumor marker tests) for an occult but impending re-
currence in asymptomatic patients (21). These investigations
would be performed serially to identify recurrent disease before
it is clinically evident, with the hope that treatment initiation
will either prevent subsequent symptomatic metastases or pro-
long overall survival (OS). However, it has been emphasized
that simply demonstrating the appearance of asymptomatic
metastases is not sufficient to support routine use of more in-
tensive screening (21). Rather, doing so must result in improved
clinical cancer outcomes, ideally improved OS or quality of life.
In this regard, five prospective, randomized clinical trials
have compared outcomes for patients who have undergone in-
tensive vs nonintensive screening. Because these studies were
performed several decades ago, the diagnostic imaging was
crude by today’s standards (chest X ray, liver ultrasound, and
bone scan). A Cochrane review of these studies (22) found high-
quality evidence of no effect of intensive screening on OS (haz-
ard ratio [HR] ¼ 0.98, 95% confidence interval [CI] ¼ 0.84 to 1.15)
Table 1. Association of tumor size, nodal status, and grade with risk
of recurrence in years 5 to 10 and 10 to 20*
Women
event free
at 5 y
Total No.
Annual rate
of distant
recurrence Cumulative
risk from
5 to 20 y
(%)Variable
5 to
<10 y (%)
10 to
20 y (%)
Nodal involvement
N0 28 847 1.0 1.1 15
N1–3 25 292 1.9 1.7 23
N4–9 8784 3.9 2.8 38
Tumor diameter (N0 only)
T1a or T1b: 1.0 cm 5527 0.5 0.8 10
T1c: 1.1–2.0 cm 13 875 0.8 1.1 14
T2: 2.1–3.0 cm 6700 1.5 1.4 19
T2: 3.1–5.0 cm 2745 1.7 1.4 20
Tumor grade (T1N0 only)
Low 3524 0.4 0.8 10
Moderate 7363 0.7 1.0 13
High 3054 0.9 1.5 17
*Data are for 62 923 patients with T1 or T2 ERþ disease with 0 to 9 positive nodes
that were to receive 5 years of adjuvant ET and were disease free at 5 years. Most
patients entered the study at diagnosis but some entered later, having already
received 2 to 5 years of ET, and were randomly assigned to stop therapy at
5 years. P less than .001 for all subgroup comparisons. Modified from (1). ERþ ¼
estrogen receptor positive; ET ¼ endocrine treatment.
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and low-quality evidence of no effect on disease-free survival
(DFS) (HR ¼ 0.84, 95% CI ¼ 0.71 to 1.00).
It is possible that intensive follow-up would have greater
clinical utility with newer, higher-quality imaging modalities
like computed tomography (CT) and positron emission tomog-
raphy (PET), which offer greater sensitivity and specificity over
conventional techniques, albeit with higher cost and radiation
exposure. In a systematic review of almost 30 studies investi-
gating detection of recurrence in symptomatic BC patients, PET
in addition to conventional imaging exhibited higher specificity
(93% vs 83%) and sensitivity (89% vs 79%) when compared with
conventional imaging alone (23). PET/CT offered better sensitiv-
ity (95% vs 80%) and specificity (89 vs 77%) vs CT alone. The po-
tential benefit of these modalities in the routine surveillance of
asymptomatic BC patients has not been studied.
Serial assessment of tumor markers such as cancer antigen
(CA)15-3 (the soluble moiety of the MUC-1 glycoprotein) and car-
cinoembryonic antigen (CEA) in the years following diagnosis
may be useful for the detection of distant metastatic recurrence.
Although preoperative serum levels of these tumor markers are
prognostic for shorter DFS and OS in BC patients, they could po-
tentially provide prognostic value for distant metastasis during
patient follow-up. Gion et al. (24) and Mariani et al. (25) have ex-
plored trade-offs among sensitivity, specificity, and positive
and negative predictive values when using CA15-3 and CEA to
detect recurrences. The best diagnostic accuracy was obtained
using both biomarkers jointly and combining two positivity cri-
teria. However, their “optimal” criteria were associated with a
sensitivity (58%) that was too low to be clinically useful.
Furthermore, the positive predictive value of these markers was
greatest during the first years after BC diagnosis, falling to less
than 20–30% by 10–12 years of follow-up. In separate research,
increases in CA15-3 in serially collected serum samples pro-
vided the earliest indication of a distant recurrence before clini-
cal or radiological detection in up to 55% of BC patients; the
addition of CEA measurements increased sensitivity for recur-
rence detection (26–28). However, development of appropriate
assay thresholds and serum collection timelines will be re-
quired (29) if these markers are to be considered for use in the
early detection of asymptomatic metastases.
Rather than improvement in OS, one argument for serial sur-
veillance is the reassurance provided by a negative test.
However, in the absence of clinical signs or symptoms of recur-
rence, the negative predictive value of a distant recurrence over
the succeeding 6 months (a reasonable time period between
testing) approaches 99% without the marker results (24,30).
Indeed, preferences for intensive vs standard follow-up differ
among patients, who may express either feelings of security as-
sociated with additional monitoring or increased anxiety over
receiving the results (21).
The recent advent of high-sensitivity blood tests for circulat-
ing tumor cells (CTCs) or circulating tumor DNA (ctDNA) may af-
fect our ability to detect BC recurrences in a time frame that
allows administration of effective and perhaps potentially cura-
tive therapy in asymptomatic patients without any evidence of
systemic disease. However, although these new modalities pro-
vide provocative possibilities, it has not been established
whether use of these modalities in asymptomatic patients leads
to better patient outcomes (OS or metastasis-free survival)
rather than simply moving forward the time of diagnosis of in-
curable metastases. These newer approaches are discussed in
greater detail in our companion paper.
Taken together, these results are the basis for current
American Society of Clinical Oncology and National Cancer
Center Network guidelines that recommend that BC survivors
undergo regular clinical assessment (history, physical examina-
tion) and breast imaging without other systemic imaging proce-
dures or tumor marker assessment (12,31).
Endocrine Interventions That Could Potentially
Reduce the Risk of Late Recurrence
The fundamental reason to more accurately identify those
without vs those with a credible risk of recurrence is to deter-
mine who might be spared, or benefit from, further therapy to
reduce or prevent the recurrence. In this regard, 5 years of adju-
vant ET, consisting of tamoxifen, aromatase inhibitors (AIs), or
some sequencing of both, considerably reduces the risk of dis-
ease recurrence (locoregional and distant) and death from BC
(32,33). Recent research has focused on the potential for ex-
tended (defined as treatment beyond 5 years) adjuvant ET to
have similar effects on the risk of late recurrence.
Extended Tamoxifen Therapy
Several trials (including Adjuvant Tamoxifen–To Offer More?
[aTTom]; Adjuvant Tamoxifen Longer Against Shorter [ATLAS];
Eastern Cooperative Oncology Group [ECOG]; E4181/E5181,
National Surgical Adjuvant Breast and Bowel Project [NSABP B-
14], and a Scottish trial) have investigated the impact of con-
tinuing tamoxifen (vs placebo) for 5 years after an initial 5 years
Table 2. Univariate HRs and 95% CI indexes for all prognostic signatures in postmenopausal women according to nodal status during years 0 to
10*
Signature
Patient group
Node-negative disease (n¼ 591) Node-positive disease (n¼ 227)
HR ¼ (95% CI) C index (95% CI) HR ¼ (95% CI) C index (95% CI)
CTS5 1.99 (1.58 to 2.50) 0.721 (0.668 to 0.774) 1.63 (1.20 to 2.21) 0.640 (0.554 to 0.726)
IHC4 1.95 (1.55 to 2.45) 0.725 (0.665 to 0.785) 1.33 (0.99 to 1.78) 0.601 (0.511 to 0.690)
RS 1.69 (1.40 to 2.03) 0.667 (0.585 to 0.750) 1.39 (1.05 to 1.85) 0.603 (0.513 to 0.693)
BCI 2.46 (1.88 to 3.23) 0.762 (0.704 to 0.820) 1.67 (1.21 to 2.29) 0.652 (0.566 to 0.739)
ROR 2.56 (1.96 to 3.35) 0.764 (0.707 to 0.821) 1.58 (1.16 to 2.15) 0.636 (0.552 to 0.719)
EPclin 2.14 (1.71 to 2.68) 0.765 (0.716 to 0.814) 1.69 (1.29 to 2.22) 0.671 (0.590 to 0.752)
*BCI ¼ Breast Cancer Index; CI ¼ confidence interval; CTS5 ¼ Clinical Treatment Score-5 y; EPclin ¼ EndoPredict clinical score; HR ¼ hazard ratio; IHC4 ¼ immunohisto-
chemical 4 protein test; ROR ¼ PAM 50 Risk of Recurrence Score; RS ¼ Oncotype DX Recurrence Score. All HRs indicate a change of 1 SD. Adapted from (3).
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of treatment (Table 3) (35–39). In a meta-analysis of these trials,
little effect was seen on risk of recurrence during years 5–9
(while treatment was being administered, odds ratio ¼ 1.01, 95%
CI ¼ 0.79 to 1.29), consistent with a beneficial carryover effect of
the first 5 years of treatment in patients receiving placebo dur-
ing years 5–9. Reduced risk was seen beyond 10 years (odds ratio
¼ 0.88, 95% CI ¼ 0.77 to 1.01) (34), reflecting carryover of the ef-
fect of tamoxifen that was administered during years 5–10. In
the largest of these, the ATLAS trial, the risk of recurrence at
15 years postdiagnosis was 25.1% vs 21.4% (P¼ .002) and of death
was 15.0% vs 12.2% (P¼ .01) for patients receiving placebo vs ex-
tended tamoxifen, respectively (36).
Extended AI Therapy
As with tamoxifen, several studies have examined potential
benefits of extended adjuvant AI therapy in postmenopausal
women after an initial 5 years with tamoxifen, tamoxifen for
2–3 years followed by an AI for the remainder of the first 5 years,
or an AI for the full first 5 years (Table 4). However, the results
are not as clearly positive as they are for extended tamoxifen.
For example, in one study (MA17R), patients were randomly
assigned to letrozole or placebo for 5 years after completing 4.5–
6 years of adjuvant therapy with an AI, preceded in most cases
by treatment with tamoxifen (41). At a median follow-up of
6.3 years from randomization, letrozole led to improved DFS (HR
¼ 0.66, 95% CI ¼ 0.48 to 0.91, P¼ .01). However, there was no sta-
tistically significant impact on distant recurrences (42 vs
53 recurrences) or OS (HR ¼ 0.97, 95% CI ¼ 0.73 to 1.28, P¼ .83).
Likewise, in a separate study (NSABP B-42), patients were
randomly assigned to letrozole vs placebo after receiving 5 years
of either an AI or up to 3 years of tamoxifen followed by an AI to
complete 5 years. DFS and distant DFS (DDFS) were improved in
the letrozole arm (HR ¼ 0.85, P¼ .048; though this did not cross a
predefined statistical significance level, and HR ¼ 0.72, P¼ .03,
respectively), but there was no effect on OS (HR ¼ 1.15, P¼ .22)
(42,43). In two other trials (the Investigation on the Duration of
Extended Adjuvant Letrozole treatment [IDEAL] and Different
Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years
Tamoxifen Therapy in Breast Cancer [DATA] trials), patients
were either randomly assigned to 2.5 vs 5 years of letrozole after
5 years of tamoxifen, AI, or a combination of AI and tamoxifen
(the IDEAL trial) or to 3 vs 6 years of anastrozole after 2–3 years
of tamoxifen (the DATA trial). In the IDEAL trial, DFS, DDFS, and
OS were similar in the two arms after a median of 6.6 years from
randomization (44). In the DATA trial, a trend toward improved
DFS (HR ¼ 0.79, 95% CI ¼ 0.62 to 1.02, P¼ .07) was observed for
the extended treatment group, driven largely by a reduction in
contralateral BCs and secondary non-BCs rather than differen-
ces in locoregional or distant recurrences (45).
A meta-analysis by the Early Breast Cancer Trialists’
Collaborative Group including 22 192 patients enrolled in 11 ran-
domized trials evaluating AI therapy (vs placebo) at 5 or more
years after diagnosis indicated a 5-year reduction in any recur-
rence (distant, local, or new primary), distant recurrence, and
BC mortality of 3.6% (P< .001), 1.5% (P¼ .008), and 0.8% (P¼ .05),
respectively, for trials of an AI after 5 years of tamoxifen
(n¼ 7483). For trials of an AI after 5–10 years of tamoxifen fol-
lowed by AI, there was a 2.1% (P¼ .002) reduction in risk of any
recurrence, but there was no beneficial effect on other end-
points (0.3% lower distant recurrence and 0.2% lower BC mortal-
ity, P¼ .09 and 0.45, respectively; N¼ 2304). Similarly, for those
receiving extended AI after 5 years of AI alone, there was a mod-
est reduction in risk of any recurrence (1.2%, P¼ .02), but no dif-
ferences in other endpoints (n¼ 3322). When including all trials,
the 5-year reduction in recurrence was 1.1% (P¼ .009) for node-
negative disease (n¼ 10 620), 3.8% (P¼ .00003) for 1–3 positive
axillary nodes (n¼ 6919), and 7.7% (P¼ .003) for four or more
positive axillary nodes (n¼ 1621) (46). Taken together, these
results suggest that extended adjuvant AI treatment is associ-
ated with potential modest beneficial effects on DFS and DDFS,
with greatest benefit observed in higher-risk patients with posi-
tive axillary nodes. No effects on OS have been reported to date,
although follow-up remains short for all these trials. Further,
the major benefit appears to be reduction in risk of local-
regional recurrence and contralateral BC, at least early on, with
few distant recurrence events even in the shorter treatment
groups.
These modest benefits of extended tamoxifen or AIs occur in
the face of common side effects that reduce quality of life (cli-
macteric and musculoskeletal symptoms) and uncommon seri-
ous toxicities (thrombosis and endometrial cancers with
tamoxifen; osteoporosis and fracture with the AIs). Indeed, con-
tinuation of tamoxifen (vs placebo) from 5 to 10 years is associ-
ated with increased risk of endometrial cancer (HR ¼ 1.74,
P¼ .002) and pulmonary embolus (HR ¼ 1.87, P¼ .01), translating
to an absolute increase of 0.2% in risk of death from endometrial
Table 3. Summary of trials examining impact of extended tamoxifen therapy
Trial name
Median
follow-up, y
Sample
size
Length of
treatment in
control arm, y
Length of
treatment in
experimental arm, y OR for recurrence 95% CI P
ATLAS 7.6* 6846 5 10 0.84 0.74 to 0.94 .003
aTTom 9† 6953‡ 5 10 0.84 0.74 to 0.95 .006
ECOG E4181/E5181 9.6 140k 5 Indefinite 0.33 0.15 to 0.70 .004
NSABP B-14 7 1172 5 10 1.18 0.80 to 1.72 .41
Scottish 10 132§ 5 Indefinite 0.93 0.46 to 1.92 .85
*Results for estrogen receptor (ER)-positive patients. Mean listed. ATLAS ¼ Adjuvant Tamoxifen Longer Against Shorter; aTTom ¼ Adjuvant Tamoxifen–To Offer More?;
CI ¼ confidence interval; ECOG E4141/E5181 ¼ Eastern Cooperative Oncology Group; NSABP B-14 ¼ National Surgical Adjuvant Breast and Bowel Project; OR ¼ odds ratio;
Scottish ¼ Scottish adjuvant tamoxifen trial a randomized study updated to 15 years.
†Estimated follow-up.
‡Whole cohort analyzed (40% ER positive, 60% ER untested).
§ER level less than 20 fmol/mg on ligand-binding assay deemed ER negative and excluded.
kFollow-up for ER-positive group is shorter than for the whole study population.
Modified from (34).
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cancer or pulmonary embolism. In contrast, risk of ischemic
heart disease (HR ¼ 0.76, P¼ .02) and contralateral BC were
lower (HR ¼ 0.88, P¼ .05), with a 3% reduction in BC mortality
and, ultimately, a net survival benefit of 2.7% in favor of ex-
tended tamoxifen (36). In MA17R, extended AI treatment was
associated with increased fracture and new-onset osteoporosis
risk (14% vs 9%, P¼ .001 and 11% vs 6%, P< .001) as well as
greater rates of arthralgia and bone pain. However, extended AI
(vs placebo, as opposed to tamoxifen in early adjuvant trials)
was not associated with an increased risk of cardiovascular
events in a recent meta-analysis (HR ¼ 1.01, 95% CI ¼ 0.85 to
1.20) (36,47). Consequently, the benefits of extending ET must be
carefully measured against the increased risk of serious adverse
toxicities. Furthermore, these potentially harmful side effects
are accompanied by concerning rates of noncompliance.
Several studies have documented that adherence to tamoxifen
and AIs decreases at a constant rate over time in a clinical trial
setting; in the DATA trial, compliance was 84% at 3 years and
66% at 6 years, and rates were 73.5% and 57.5% at 2.5 and 5 years
in the IDEAL trial (44,45).
The use of extended ET is common, particularly in higher-
risk patients, often determined by clinical and pathologic fea-
tures such as larger tumors or those with lymph node involve-
ment. Although DDFS and OS benefits of extended tamoxifen
have been clearly demonstrated, they are modest. Benefits of
AIs are less clear, although follow-up is short. It is a high prior-
ity to develop means, beyond standard clinical or pathologic
features, that identify those at increased risk for recurrence and
greatest likelihood of benefitting from extended treatment.
Since completion of the workshop, some adjuvant trials involv-
ing CDK4/6 inhibitors have been initiated (reviewed in [48]).
Results of these trials will be informative, and there may be a
role for these agents in extended treatment and late-recurrence
reduction.
Potentially Modifiable Host and Other Factors
That May Contribute to Late Recurrence
Another possible approach to reduce the problem of late recur-
rence could involve the identification, and subsequent avoid-
ance, of potentially modifiable host-related factors that might
affect reactivation of cancer cells from dormancy (dormancy is
discussed in detail in a companion manuscript in this issue).
Potential exposures of interest include stimulation of growth
factors by trauma and/or surgery, selected lifestyles including
physical inactivity and obesity, use or nonuse of certain nonan-
tineoplastic medications, and the development or existence of
comorbidities (diabetes, immune disorders, stress) (Table 5).
The limited evidence linking these factors to late recurrence is
summarized briefly below.
Trauma or Surgery
Numerous cytokines and growth and angiogenic factors that
may contribute to exit from dormancy and tumor outgrowth are
released during wound healing in response to trauma (surgery
or accidental injury) events, which have been postulated to be
associated with late recurrence (49–52). Most reports examining
this relationship have focused on early or delayed breast recon-
struction surgery. Initial observational studies suggested that
risk of recurrence or mortality was lower after delayed breast re-
construction vs early or no reconstruction (53). Most, if not all,
of these studies were retrospective, observational cohorts with
no high-level randomized evidence to support the theory. The
design of these studies may also have introduced a selection
bias, in part, because events were analyzed from the time of BC
diagnosis rather than the time of reconstruction (ie, patients
who had experienced a distant recurrence would be less likely
to have undergone reconstruction, leading to a spuriously lower
risk in the reconstruction group). When recurrence in patients
undergoing delayed tissue reconstruction vs not (controls) was
compared from the time of reconstruction, using a matched
time in controls (ie, a landmark analysis that may minimize the
effect of time-related bias), there was an increased risk of recur-
rence in those undergoing reconstruction (HR ¼ 2.08, 95% CI ¼
1.07 to 4.06) (54). However, in a retrospective analysis of patients
enrolled in the Arimidex, Tamoxifen, Alone or in Combination
(ATAC) and Long-term Anastrozole versus Tamoxifen
Treatment Effects (LATTE) trials, those who had trauma or
Table 4. Summary of trials examining impact of extended AI therapy*
Trial name Median follow-up, y Control arm (No.) Experimental arm (No.) HR DFS (95% CI) Prior ET
MA17R 6.3 Placebo (959) Letrozole 5 y (959) 0.66 (0.48 to 0.91) Tamoxifen (0–6 y), AIs (4.5–6 y)
MA17 2.5 Placebo (2577) Letrozole 5 y (2572) 0.58 (0.45 to 0.76) Tamoxifen 5 y
DATA 4.1 Anastrozole 3 y (833) Anastrozole 6 y (827) 0.79 (0.62 to 1.02) Tamoxifen 2–3 y
IDEAL 6.6 Letrozole 2.5 y (898) Letrozole 5 y (903) 0.96 (0.76 to 1.2) Endocrine therapy 5 y
NSABP B-42 6.9 Placebo (1964) Letrozole 5 y (1959) 0.85 (0.73 to 1.00) Endocrine therapy 5 y
*Modified from (40). AI ¼ aromatase inhibitor; CI = confidence interval; DATA = Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen
Therapy in Breast Cancer; DFS ¼ disease-free survival; ET = endocrine treatment; HR = hazard ratio; IDEAL = Duration of Extended Adjuvant Letrozole treatment;
NSABP = National Surgical Adjuvant Breast and Bowel Project B-42.
Table 5. Putative host factors that potentially modulate BC
recurrence*
Host factor Characteristic
Surgery, trauma Breast reconstruction, early or delayed
Lifestyle Body size (adiposity)
Physical activity
Diet
Psychosocial, stress
Others (alcohol, tobacco)
Medications Bone agents (bisphosphonates,
RANK-L inhibitors)
Metabolic agents (metformin, insulin)
Anti-inflammatory agents (aspirin)
Hormonal agents (tibolone)
Others
Comorbid disease Diabetes
Immune disorders
Others
*BC ¼ breast cancer; RANK-L ¼ RANK-ligand.
6 of 10 | JNCI Cancer Spectrum, 2019, Vol. 3, No. 4
D
ow
nloaded from
 https://academ
ic.oup.com
/jncics/article-abstract/3/4/pkz050/5545979 by C
hester Beatty R
esearch Institute user on 30 D
ecem
ber 2019
surgery (excluding breast reconstruction) did not experience an
increased risk of recurrence; the use of ET and the inclusion
both of major and minor trauma or surgical events may have
obscured any risk associated with these events (55). Based on
available data, it is unclear whether surgery or trauma contrib-
utes to late recurrence in patients not on concurrent ET.
Lifestyle
Obesity at BC diagnosis has been associated with a higher risk
of recurrence both before and after 5 years postdiagnosis (56–
58). There is evidence that obesity-associated factors such as
leptin (which affects JAK-STAT signaling), but not insulin or glu-
cose, may mediate this association, potentially affecting exit
from dormancy (56). Physical activity (either prediagnosis or
postdiagnosis) has been consistently associated with better BC
outcomes in observational studies. In one study, physical activ-
ity after completion of adjuvant ET (mean of 5.6 years after diag-
nosis) was inversely associated with subsequent BC mortality
(ie, >21 metabolic equivalent (MET)-hours/week vs <2.8 MET-
hours per week (HR ¼ 0.44, 95% CI ¼ 0.32 to 0.66) (59). Owing to
the potential for a healthy-person bias in nonobese or active
patients, it cannot be concluded that these associations are
causal (or reversible). Intervention research in the late-recur-
rence setting similar to that ongoing in the adjuvant setting [eg,
the Alliance for Clinical Trials in Oncology Breast Cancer
Weight Loss trial, BWEL trial (60)] will be necessary to provide
definitive evidence that changing lifestyle will lower risk of late
BC recurrence. Other lifestyle-related factors including dietary
composition, smoking and alcohol consumption, as well as psy-
chological factors (such as social isolations or stress) that have
been postulated to be associated with BC recurrence (but not
specifically late recurrence) may also affect risk of late recur-
rence in patients with BC; however, data are sparse. At present,
although it is preferable for any individual to pursue a healthy
lifestyle, there are no data to support substituting such a strat-
egy for pharmacologic adjuvant treatment, such as extended
ET, or for adding lifestyle modification to extended ET in the
contexts in which extended ET has proven efficacy.
Nonantineoplastic Medications
A variety of medications not directed toward neoplastic cells
themselves may affect tumor dormancy. Perhaps the most rele-
vant are agents used to modify bone (when used for nonneo-
plastic indications), such as bisphosphonates (zoledronic acid,
ibandronate, clodronate) and the anti-RANK ligand agent, deno-
sumab. The bisphosphonates have been linked to modestly re-
duced rates of disease recurrence in postmenopausal women
with early-stage BC, but these small benefits were not confined
to ERþ disease (61,62). Because dormancy may be particularly
evident in bone, it has been suggested that bisphosphonates
might prevent escape from dormancy by altering the bone mi-
croenvironment (63,64). However, there is little if any evidence
that prolonged bisphosphonate therapy does, indeed, prevent
late (as opposed to earlier) relapse. There is also no consistent
evidence that denosumab is effective in the late-recurrence
setting.
Several observational studies have suggested that other
medications may also be associated with improved BC out-
comes, including statins [HR for distant recurrence-free interval
¼ 0.74, 95% CI ¼ 0.56 to 0.93 (65)], aspirin [HR ¼ for BC-specific
mortality 0.42, 95% CI ¼ 0.31 to 0.55 (66)], metformin [HR for all-
cause mortality ¼ 0.55, 95% CI ¼ 0.44 to 0.70) (67)], and beta-
blockers [HR ¼ for BC death 0.50, 95% CI ¼ 0.32 to 0.80 (68)].
These studies did not focus on associations with late vs early
events, and they were subject to selection, allocation, and sur-
vival biases and cannot provide evidence of causality.
Adjuvant trials of metformin [fully accrued (69)] and aspirin
(accrual ongoing) will provide definitive evidence regarding the
effectiveness of these agents both on early and late BC recur-
rence. Of concern, despite observational evidence suggesting a
beneficial effect, a randomized trial of celecoxib (vs placebo)
failed to identify an effect of the drug on risk of recurrence at
any time (70).
In contrast, in a randomized trial, the synthetic estrogenic
hormone tibolone increased the risk of recurrence in BC survi-
vors, even when administered years after diagnosis (HR ¼ 1.40,
95% CI ¼ 1.14 to 1.70, P¼ .001), including among patients with
ERþ cancer who were receiving adjuvant ET (71). These findings
are hypothesized to be the result of proliferative effects exerted
by tibolone on dormant luminal BC cells (72).
Comorbid Diseases
Diabetes has been associated with poor BC outcomes, including
increased risk both of noncancer and BC-related deaths (73,74).
Given the observational nature of this evidence, it is not clear
that these associations, if real, are causal or coincidental, and it
is also not clear whether the increased risk extends to late
recurrences in ERþ BC.
Taken together, these host-related factors are of interest be-
cause many are potentially avoidable or modifiable. Standardized
assessment of these factors in cohorts of patients with BC would
provide valuable information regarding their relationships with
dormancy and disease recurrence.
Conceptualization of Risk of Late Recurrence:
Three Potential Scenarios
Given our current inability to identify individual patients who
will develop late recurrences, it is useful to conceptualize three
categories (fully described in our companion article, (2)) of
patients in relation to “tumor dormancy” and its role in the de-
velopment of late recurrence: 1) no dormant cells present, 2)
dormant cells present that remain dormant, and 3) dormant
cells present that have escaped dormancy. Although we use the
term “dormancy” here, we recognize that other cellular mecha-
nisms may contribute to early and/or late recurrence, and there
is likely a continuum of dormancy including mixed cell popula-
tions that culminate in clinical development of metastases once
a critical threshold is reached. Although it is not currently possi-
ble to place individual patients into these conceptual categories,
emerging technologies (such as CTCs and ctDNA) may make
this possible in the future. Importantly, from a theoretical per-
spective these categories can guide research and, once vali-
dated, may ultimately inform treatment decisions, notably
decisions around extended adjuvant ET or introduction of novel
therapies in the extended adjuvant setting.
In the face of a growing appreciation of the potential for late
recurrence in ERþ BC, participants in this workshop reviewed
the current data showing the absolute risk of recurrence varied
from less than 1% to greater than 3% per year, with the annual
risk remaining constant from 5 to 15 years postdiagnosis (1). Risk
was dependent on traditional clinicopathologic characteristics,
notably tumor size and nodal stage; emerging evidence suggests
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that immunohistochemical and gene-based tumor evaluation
may help to refine this risk. The use of extended adjuvant ET, al-
though endorsed by guidelines committees, was recognized to
have only a modest impact on the risk of late distant recur-
rences. There was agreement that understanding and treating
late recurrence in ERþ BC was a major, unmet clinical need.
To date, research has shown that routine surveillance
for late recurrences may lead to early identification of asymp-
tomatic metastases but has not led to improved BC outcomes.
Existing research was largely conducted before the era of more
sensitive CT-, PET-, and MRI-based imaging, and it is possible
that routine imaging using these modalities may lead to greater
detection of asymptomatic metastases; however, this approach
was not expected to identify recurrences sufficiently early that
intervention would lead to improved BC outcomes. Similarly,
routine evaluation of tumor markers (eg, CEA, CA 15-3) does not
appear to improve outcomes. There was a consensus that more
refined approaches to detecting asymptomatic late recurrences
that were potentially curable were urgently needed. Such
approaches could include emerging CTC and ctDNA technolo-
gies; rigorous evaluation of these technologies will be required
before they are used routinely in the clinical setting. These
issues are discussed more fully in the companion article (2).
In parallel to this research, reflecting advances in under-
standing tumor dormancy, there was recognition that host fac-
tors including obesity, diabetes, and trauma or surgery may
contribute to late recurrence by contributing to the escape of
cancer cells from dormancy, and noncancer-targeted drugs may
modify this risk. Although evidence supporting the contribu-
tions of each of these factors to late recurrence specifically (as
opposed to an association with prognosis in general) is weak,
further investigation of these potentially reversible or avoidable
factors in future late-recurrence research was embraced by
workshop participants.
The concept of tumor dormancy (and indolence), emerging
technologies to identify escape from dormancy, and research
priorities designed to prevent and/or treat late recurrence to im-
prove cancer outcomes are discussed in the companion paper.
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